CytomX Therapeutics (CTMX) Competitors $0.80 +0.04 (+5.90%) Closing price 04:00 PM EasternExtended Trading$0.81 +0.00 (+0.50%) As of 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CTMX vs. DRUG, HUMA, PLX, KOD, SLRN, AARD, PRME, SOPH, NGNE, and CRGXShould you be buying CytomX Therapeutics stock or one of its competitors? The main competitors of CytomX Therapeutics include Bright Minds Biosciences (DRUG), Humacyte (HUMA), Protalix BioTherapeutics (PLX), Kodiak Sciences (KOD), Acelyrin (SLRN), Aardvark Therapeutics (AARD), Prime Medicine (PRME), SOPHiA GENETICS (SOPH), Neurogene (NGNE), and CARGO Therapeutics (CRGX). These companies are all part of the "pharmaceutical products" industry. CytomX Therapeutics vs. Bright Minds Biosciences Humacyte Protalix BioTherapeutics Kodiak Sciences Acelyrin Aardvark Therapeutics Prime Medicine SOPHiA GENETICS Neurogene CARGO Therapeutics CytomX Therapeutics (NASDAQ:CTMX) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, community ranking, analyst recommendations and profitability. Does the MarketBeat Community prefer CTMX or DRUG? CytomX Therapeutics received 369 more outperform votes than Bright Minds Biosciences when rated by MarketBeat users. However, 100.00% of users gave Bright Minds Biosciences an outperform vote while only 65.22% of users gave CytomX Therapeutics an outperform vote. CompanyUnderperformOutperformCytomX TherapeuticsOutperform Votes37565.22% Underperform Votes20034.78% Bright Minds BiosciencesOutperform Votes6100.00% Underperform VotesNo Votes Do analysts prefer CTMX or DRUG? CytomX Therapeutics presently has a consensus price target of $4.77, suggesting a potential upside of 484.15%. Bright Minds Biosciences has a consensus price target of $84.33, suggesting a potential upside of 163.13%. Given CytomX Therapeutics' higher possible upside, equities research analysts clearly believe CytomX Therapeutics is more favorable than Bright Minds Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CytomX Therapeutics 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Bright Minds Biosciences 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has higher valuation & earnings, CTMX or DRUG? CytomX Therapeutics has higher revenue and earnings than Bright Minds Biosciences. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytomX Therapeutics$138.10M0.47-$570K$0.382.15Bright Minds BiosciencesN/AN/A-$2.06M-$0.17-188.53 Which has more volatility & risk, CTMX or DRUG? CytomX Therapeutics has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, Bright Minds Biosciences has a beta of -5.5, indicating that its stock price is 650% less volatile than the S&P 500. Does the media refer more to CTMX or DRUG? In the previous week, CytomX Therapeutics had 1 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 6 mentions for CytomX Therapeutics and 5 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.54 beat CytomX Therapeutics' score of 0.71 indicating that Bright Minds Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bright Minds Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is CTMX or DRUG more profitable? CytomX Therapeutics has a net margin of 10.96% compared to Bright Minds Biosciences' net margin of 0.00%. Bright Minds Biosciences' return on equity of -5.85% beat CytomX Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CytomX Therapeutics10.96% -41.47% 8.11% Bright Minds Biosciences N/A -5.85%-5.68% Do institutionals & insiders have more ownership in CTMX or DRUG? 67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 7.0% of CytomX Therapeutics shares are owned by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryCytomX Therapeutics beats Bright Minds Biosciences on 11 of the 18 factors compared between the two stocks. Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTMX vs. The Competition Export to ExcelMetricCytomX TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$65.44M$6.85B$5.55B$8.05BDividend YieldN/A2.95%5.09%4.22%P/E Ratio4.817.4722.7418.81Price / Sales0.47261.18406.26107.19Price / CashN/A65.8538.1834.62Price / Book-1.156.616.814.35Net Income-$570,000.00$143.37M$3.22B$247.85M7 Day Performance15.07%3.83%2.33%2.85%1 Month Performance34.22%6.22%3.68%4.29%1 Year Performance-81.84%-2.23%16.88%5.92% CytomX Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTMXCytomX Therapeutics4.2227 of 5 stars$0.80+5.9%$4.77+495.1%-85.2%$64.24M$138.10M4.72170Upcoming EarningsDRUGBright Minds Biosciences3.3552 of 5 stars$32.18-1.6%$84.33+162.1%+2,844.2%$226.68MN/A-189.28N/ANews CoveragePositive NewsGap UpHUMAHumacyte2.6652 of 5 stars$1.46+1.4%$13.71+839.3%-68.0%$226.47M$1.57M-1.09150Upcoming EarningsPLXProtalix BioTherapeutics2.8093 of 5 stars$2.85flat$15.00+426.3%+147.9%$222.39M$53.40M-21.92200Analyst RevisionNews CoveragePositive NewsKODKodiak Sciences4.0406 of 5 stars$4.21+2.4%$9.00+113.8%+27.2%$222.07MN/A-1.1590News CoveragePositive NewsSLRNAcelyrin2.9658 of 5 stars$2.18+0.5%$9.60+340.4%-39.3%$219.98MN/A-0.89135News CoveragePositive NewsAARDAardvark TherapeuticsN/A$10.12+27.6%$31.50+211.3%N/A$219.56MN/A0.0018PRMEPrime Medicine2.4462 of 5 stars$1.66-1.8%$13.38+705.7%-67.0%$217.73M$2.98M-0.81234SOPHSOPHiA GENETICS2.3865 of 5 stars$3.26+3.2%$6.80+108.6%-40.1%$217.40M$65.17M-2.99520Upcoming EarningsNews CoverageHigh Trading VolumeNGNENeurogene1.8591 of 5 stars$14.50-5.9%$47.20+225.5%-54.4%$216.49M$925,000.00-3.4090Upcoming EarningsPositive NewsCRGXCARGO Therapeutics2.1046 of 5 stars$4.63+2.7%$15.00+224.0%-78.7%$213.22MN/A-1.09116News CoveragePositive News Related Companies and Tools Related Companies Bright Minds Biosciences Competitors Humacyte Competitors Protalix BioTherapeutics Competitors Kodiak Sciences Competitors Acelyrin Competitors Aardvark Therapeutics Competitors Prime Medicine Competitors SOPHiA GENETICS Competitors Neurogene Competitors CARGO Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTMX) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
